Department of Health and Human Services
National Institutes of Health
Toggle navigation
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
Help & Search Tips
Contact Us
National Cancer Institute (NCI)s
National Cancer Institute (NCI)
444 Protocols (228 Active Accrual of new subjects, 216 Follow-up of previously enrolled subjects)
20-C-0045:
Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies
20-C-0028:
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
20-C-0027:
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
20-C-0024:
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
20-C-0022:
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
20-C-0013:
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
20-C-0009:
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
19-C-0129:
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
19-C-0117:
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
19-C-0104:
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
19-C-0103:
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
19-C-0102:
A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple Myeloma
19-C-0094:
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
19-C-0062:
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
19-C-0061:
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
19-C-0046:
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
19-C-0042:
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
19-C-0041:
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
19-C-0033:
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
19-C-0030:
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma
19-C-0010:
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
19-C-0006:
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
18-C-0143:
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
18-C-0138:
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
18-C-0135:
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
18-C-0125:
A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma
18-C-0122:
Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
18-C-0110:
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
18-C-0080:
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial
18-C-0078:
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)
18-C-0062:
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
18-C-0059:
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
18-C-0058:
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
18-C-0056:
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
18-C-0033:
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
18-C-0028:
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
18-C-0024:
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
18-C-0008:
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
18-C-0005:
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
17-C-0158:
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
17-C-0157:
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Guerin (BCG)
17-C-0153:
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy
17-C-0102:
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
17-C-0100:
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
17-C-0092:
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
17-C-0089:
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
17-C-0086:
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
17-C-0074:
A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma
17-C-0066:
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
17-C-0048:
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
17-C-0043:
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
17-C-0034:
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
17-C-0011:
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
17-C-0009:
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide (tmz) Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastom
16-C-0171:
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
16-C-0154:
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
16-C-0151:
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
16-C-0135:
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
16-C-0121:
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
16-C-0107:
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
16-C-0094:
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
16-C-0092:
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
16-C-0088:
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritonea
16-C-0087:
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
16-C-0081:
A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma
16-C-0073:
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
16-C-0060:
A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
16-C-0048:
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
16-C-0047:
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
16-C-0043:
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
16-C-0035:
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
16-C-0034:
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
16-C-0011:
A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
16-C-0009:
Phase II trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi- Center Trial
15-C-0200:
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
15-C-0160:
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
15-C-0157:
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
15-C-0145:
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
15-C-0142:
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
15-C-0116:
Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
15-C-0099:
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
15-C-0078:
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
15-C-0076:
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
15-C-0067:
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
15-C-0029:
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
15-C-0019:
The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1
14-C-0163:
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
14-C-0161:
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
14-C-0116:
A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors
14-C-0079:
An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Chronic Illnesses
14-C-0037:
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
14-C-0036:
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 I
14-C-0004:
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
14-C-0001:
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
13-C-0153:
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate Cancer
13-C-0152:
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
13-C-0146:
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer
13-C-0118:
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
13-C-0105:
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
12-C-0205:
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Previous 100 Protocols
Next -400 Protocols